EP 3302539 A4 20181219 - MANUFACTURING MULTI-DOSE INJECTION READY DENDRITIC CELL VACCINES
Title (en)
MANUFACTURING MULTI-DOSE INJECTION READY DENDRITIC CELL VACCINES
Title (de)
HERSTELLUNG VON INJEKTIONSFERTIGEN MEHRFACHDOSIS-IMPFUNGEN AUS DENDRITISCHEN ZELLEN
Title (fr)
FABRICATION DE VACCINS MULTIDOSES PRÊTS À INJECTER À BASE DE CELLULES DENDRITIQUES
Publication
Application
Priority
- US 201562165445 P 20150522
- US 2015041022 W 20150717
- US 2016021090 W 20160305
Abstract (en)
[origin: WO2016190940A1] The present embodiments relate to an FDA- approved injectable multi-dose antigen pulsed dendritic cell (DC) vaccine. In one embodiment, the activated antigen-loaded DC vaccine comprises an initial immunizing dose and multiple "booster"doses. Also provided is a method of blocking both HER-2 and HER-3 as a treatment in causing permanent tumor senescence in HER-2 expressing breast cancers. Also provided is combination anti-estrogen therapy and anti-HER2 dendritic call vaccination for ERpos/HER2pos DCIS breast cancer patients.
IPC 8 full level
A61K 39/00 (2006.01); A61K 35/12 (2015.01); A61K 35/14 (2015.01); A61K 35/28 (2015.01); A61K 39/385 (2006.01); A61K 39/395 (2006.01); C07K 1/00 (2006.01); C07K 2/00 (2006.01); C07K 14/00 (2006.01); C12N 5/00 (2006.01)
CPC (source: EP)
A61K 39/385 (2013.01); A61K 39/4615 (2023.05); A61K 39/4622 (2023.05); A61K 39/464406 (2023.05); A61P 35/00 (2018.01); A61P 43/00 (2018.01); C07K 14/00 (2013.01); C07K 16/32 (2013.01); C12N 5/0639 (2013.01); A61K 2039/505 (2013.01); A61K 2239/31 (2023.05); A61K 2239/38 (2023.05); A61K 2239/49 (2023.05)
Citation (search report)
- [Y] US 5846538 A 19981208 - CHEEVER MARTIN A [US], et al
- [IDP] WO 2015139003 A1 20150917 - CZERNIECKI BRIAN J [US]
- [YP] WO 2016011347 A1 20160121 - UNIV PENNSYLVANIA [US], et al
- [E] WO 2016153761 A1 20160929 - CZERNIECKI BRIAN J [US]
- [E] WO 2016154508 A1 20160929 - UNIV PENNSYLVANIA [US]
- [E] WO 2016154625 A1 20160929 - CZERNIECKI BRIAN J [US]
- [X] B. J. CZERNIECKI ET AL: "Targeting HER-2/neu in Early Breast Cancer Development Using Dendritic Cells with Staged Interleukin-12 Burst Secretion", CANCER RESEARCH, vol. 67, no. 4, 15 February 2007 (2007-02-15), & 102ND ANNUAL MEETING OF THE AMERICAN-ASSOCIATION-FOR-CANCER-RESEARCH (AACR); ORLANDO, FL, USA; APRIL 02 -06, 2011, pages 1842 - 1852, XP055269484, ISSN: 0008-5472, DOI: 10.1158/0008-5472.CAN-06-4038
- [Y] MITTENDORF E A: "HER-2 Pulsed Dendritic Cell Vaccine Can Eliminate HER-2 Expression and Impact Ductal Carcinoma In Situ Sharma A, Koldovsky U, Xu S, et al (Rena Rowan Breast Ctr, Philadelphia, PA; et al)Cancer118:4354-4362, 2012$", BREAST DISEASES: A YEAR BOOK QUARTERLY, MOSBY, ST. LOUIS, MO, US, vol. 24, no. 1, 15 March 2013 (2013-03-15), pages 55 - 56, XP029001806, ISSN: 1043-321X, DOI: 10.1016/J.BREASTDIS.2013.01.029
- [T] LEA LOWENFELD ET AL: "Dendritic Cell Vaccination Enhances Immune Responses and Induces Regression of HER2 pos DCIS Independent of Route: Results of Randomized Selection Design Trial", CLINICAL CANCER RESEARCH, vol. 23, no. 12, 15 June 2017 (2017-06-15), US, pages 2961 - 2971, XP055521767, ISSN: 1078-0432, DOI: 10.1158/1078-0432.CCR-16-1924
- See also references of WO 2016190940A1
Designated contracting state (EPC)
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
DOCDB simple family (publication)
WO 2016190940 A1 20161201; CA 2986687 A1 20161201; CN 107206061 A 20170926; EP 3302539 A1 20180411; EP 3302539 A4 20181219; JP 2018515421 A 20180614; JP 2020180139 A 20201105
DOCDB simple family (application)
US 2016021090 W 20160305; CA 2986687 A 20160305; CN 201680002773 A 20160305; EP 16800434 A 20160305; JP 2017502876 A 20160305; JP 2020117004 A 20200707